CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022

27 Jul 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

26 Jul 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings

07 Jul 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

14 Jun 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference

08 Jun 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

11 May 2022 16:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology

05 May 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022

29 Apr 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference

06 Apr 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

10 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors

03 Mar 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022

01 Mar 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 10, 2022

25 Feb 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

14 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference on February 12, 2022

02 Feb 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

21 Dec 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Added to the Nasdaq Biotechnology Index

13 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings

16 Nov 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Upcoming Investor Events in November and December 2021

11 Nov 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update

10 Nov 2021 16:05:02 By Nasdaq GlobeNewswire